Immunotherapy outcomes for cancer patients
Part of Cancer clinical trials.
This study looks at how well immunotherapy (a type of cancer treatment that helps your immune system attack cancer cells) works for people with various types of cancer. You may join if you are already planning to receive this treatment, and the study will track your outcomes to help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have been diagnosed with cancer (confirmed by biopsy or other lab tests).
- Your doctor plans to give you immunotherapy (like PD-1/PD-L1 inhibitors) as part of your treatment, possibly with other treatments such as chemotherapy or radiation.
- You have at least one measurable tumor (that can be seen or measured on scans).
- Your major organs (like liver, kidneys, blood cells) are working well enough for you to receive treatment.
- You are willing to take part and follow up with the study team, and you have signed the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how well combining immunotherapy with radiation therapy works for people with various types of cancer. It aims to see how effective and safe the treatment is, and what factors might influence outcomes.
This study looks at side effects from immune checkpoint inhibitors in people with solid tumors. It aims to understand why side effects happen and who might be at risk, so doctors can better manage them.
This study uses blood and tumor samples to find markers that predict whether immunotherapy will work for people with stage IV cancer. The goal is to better match treatments to patients.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
This study looks at whether immune checkpoint inhibitors given as the first treatment work well and are safe for people with advanced (stage IV) solid tumors. You might qualify if you can take study treatment reliably and your cancer type and health match the study rules.
This is an observational study that follows adults with solid cancer who are receiving immune checkpoint inhibitor treatments. It aims to learn how these medicines are used and what outcomes may look like in everyday care.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.